ARCA biopharma
ARCA biopharma is a clinical-stage biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. Founded in 1992 in Westminster, Colorado, it operates with 11-50 employees under founder-CEO Michael R. Bristow and is financed through specialist biotech equity capital.
- Company typePrivate
- Founded1992
- HeadquartersWestminster, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ARCA biopharma does
ARCA biopharma is a clinical-stage biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. Founded in 1992 and headquartered in Westminster, Colorado, the company has operated as a small, founder-led firm with between 11 and 50 employees, and its common stock previously traded on NASDAQ under the ticker ABIO before a delisting event. The scientific premise is the use of genetic or biomarker-based targeting to identify patient subpopulations likely to respond to specific cardiovascular drug candidates, a strategy intended to improve clinical-trial efficiency and therapeutic differentiation in indications such as heart failure and arrhythmia management.
The business model is a traditional clinical-stage biotech model: the firm finances R&D through periodic equity raises (cumulative disclosed financings of approximately $90M between 2006 and 2015, with the largest 2015 round led by Venrock alongside Franklin Templeton, NEA, RA Capital, and Tekla Capital) and pursues eventual monetization through commercialization, partnership, or acquisition. The leadership team has remained founder-anchored under Michael R. Bristow (President and CEO), with Robert Conway as Chairman and supporting executives in legal, finance, and operations roles (Christopher D. Ozeroff as General Counsel; Jeff Dekker and Patrick Wheeler listed in CFO roles; Tom Keuer as COO). The input discloses no named commercial product, no partnerships, no customer base, and no revenue, indicating the firm has not yet reached commercialization. The reported financial line items (operating losses and enterprise value in the trillions of dollars) are not credible economic figures and should be treated as data artifacts rather than as evidence of scale.
ARCA biopharma firmographics
Firmographics- Name
- ARCA biopharma
- Website
- https://arcabiopharma.com
- Company type
- Private
- Founded year
- 1992
- Headcount range
- 11–50 employees
- Short description
- ARCA biopharma is a clinical-stage biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. Founded in 1992 in Westminster, Colorado, it operates with 11-50 employees under founder-CEO Michael R. Bristow and is financed through specialist biotech equity capital.
- Ownership category
- akta.pro rank
ARCA biopharma industry classification
Industry- Product category
- Cardiovascular Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)
- akta.pro secondary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where ARCA biopharma is headquartered
LocationHeadquarters
- HQ city
- Westminster
- HQ country
- United States
- HQ region
- North America
Markets served
ARCA biopharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
ARCA biopharma product offering
Product offeringCore offering
ARCA biopharma develops genetically-targeted therapies for cardiovascular diseases. The company focuses on precision medicine approaches to create pharmaceutical candidates tailored to specific genetic profiles of cardiovascular patients, integrating genetic targeting into the discovery and development of treatments for heart conditions such as heart failure and related cardiovascular indications.
Product overview
Oruka Therapeutics is developing a pipeline of novel monoclonal antibodies (ORKA-001 and ORKA-002) targeting chronic skin diseases, particularly plaque psoriasis and related conditions. The company focuses on potentially best-in-class biologics designed to deliver higher rates of complete disease clearance with infrequent dosing (one to two doses per year).
Differentiator
Problem solved
Functional benefit
Companies that use ARCA biopharma
Customer profileIdeal customer profiles2 records
ARCA biopharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
ARCA biopharma partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights3 records
ARCA biopharma competitors and assessment
Company assessmentDirect peers
- Esperion Therapeutics: Esperion develops oral CV drugs for lipid management. Comparable as a small/mid-cap commercial-stage CV pharma; useful benchmark for CV drug commercial economics and partnership dynamics.
- Cytokinetics: Cytokinetics develops cardiovascular drugs targeting heart failure and related conditions (e.g., cardiac myosin modulators). Directly comparable to ARCA as a clinical-stage CV-focused biotech targeting genetically/mechanistically defined CV populations.
- MyoKardia (acquired by Bristol Myers Squibb): MyoKardia was a clinical-stage CV precision medicine company (mavacamten for hypertrophic cardiomyopathy) acquired by BMS for $13B. Highly relevant comparable for ARCA's genetically-targeted CV thesis and as a prior exit benchmark.
- Tenaya Therapeutics: Tenaya develops genetically-targeted and gene therapy-based treatments for cardiovascular diseases including heart failure. Closely aligned with ARCA's precision-medicine approach to CV indications.
- BridgeBio Pharma: BridgeBio has a substantial cardiovascular franchise (e.g., acoramidis for transthyretin amyloid cardiomyopathy). Comparable as a mid-cap clinical-stage company targeting genetically-defined CV subpopulations.
- Corvidia Therapeutics (acquired by Novo Nordisk): Corvidia was a precision-medicine developer targeting inflammatory CV disease and was acquired by Novo Nordisk. Comparable as a small CV-focused biopharma exit case in the precision CV space.
Broad incumbents
- Novartis: Novartis markets Entresto (sacubitril/valsartan), the leading heart failure therapy, giving it broad CV franchise overlap. Relevant as a broad incumbent defining the addressable market ARCA would compete in.
- Ionis Pharmaceuticals: Ionis develops antisense oligonucleotide-based drugs including CV assets such as pelacarsen for Lp(a)-driven CV disease. Comparable as a broader-stage developer with material cardiovascular franchise and similar mechanism-targeting philosophy.
Emerging players
- Lexeo Therapeutics: Lexeo develops gene therapies for cardiac diseases including arrhythmogenic and other inherited cardiomyopathies. Comparable emerging player applying genetic-targeting to CV therapeutics, similar end-patient populations.
- Verve Therapeutics: Verve is a clinical-stage developer of in vivo gene editing therapies for cardiovascular disease (e.g., PCSK9, ANGPTL3). Comparable as a genetic-medicine company targeting CV indications with similar business model.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights4 records
Customer concentration
ARCA biopharma social profiles
Digital presenceARCA biopharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
ARCA biopharma leadership team
Management profileNumber of profiles
Profiles6 records
ARCA biopharma funding detail
Funding detailFunding overview
Funding rounds5 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ARCA biopharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ARCA biopharma
What does ARCA biopharma do?
ARCA biopharma develops genetically-targeted therapies for cardiovascular diseases. The company focuses on precision medicine approaches to create pharmaceutical candidates tailored to specific genetic profiles of cardiovascular patients, integrating genetic targeting into the discovery and development of treatments for heart conditions such as heart failure and related cardiovascular indications.
When was ARCA biopharma founded?
ARCA biopharma was founded in 1992. It employs 11 to 50 people.
Where is ARCA biopharma based?
ARCA biopharma is headquartered in Westminster, United States, in the North America region.
Who are ARCA biopharma's main competitors?
Direct peers on record are Esperion Therapeutics, Cytokinetics, MyoKardia (acquired by Bristol Myers Squibb), Tenaya Therapeutics, BridgeBio Pharma and Corvidia Therapeutics (acquired by Novo Nordisk). Broad incumbents are Novartis and Ionis Pharmaceuticals. Emerging players are Lexeo Therapeutics and Verve Therapeutics.
Does ARCA biopharma have an API?
No public API is recorded for ARCA biopharma.
What industry is ARCA biopharma in?
ARCA biopharma's product category is Cardiovascular Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 541714.